REGN Regeneron Pharmaceuticals, Inc.

$601.65▼ -2.36% Healthcare Other Last sync: just now Syncing
Key Metrics & Fundamentals
Market Cap
$63.08B
P/E Ratio
15.0
Div Yield
0.62%
52W Range
503.25 - 821.11
% vs 50 MA
-12.20%
% vs 200 MA
-11.48%
RSI-14
36.7
MACD Histogram
+1.7500
Beta (1Y vs SPY)
0.47
Free Cash Flow
$799.40M
Gross Rev
$3.61B
Gross Profit
$2.94B
EBITDA
$1.04B
COGS
$669.40M
Operating Exp
$2.19B
Operating Income
$744.80M
EBIT
$744.80M
Pretax Income
$831.20M
Net Income
$727.20M
EPS (Diluted)
6.75
Price & Volume History
Volume (M)
Financial Overview - Income Statement Quarterly
Social Sentiment
Avg +0.64 · 13 posts
PriceTargetDiscussionHere's 5 value plays trading at multi-year PE lows
r/StockMarket · Sep 4, 2025
REGN is analyzed as a value play with a lower P/B ratio and growth potential.
positive +0.60
DDNewsDiscussionMy 3 Undervalued Companies Finds Of The Week
r/StockMarket · Aug 29, 2025
The post describes Regeneron's financials as ‘almost too good’ and presents a positive outlook.
positive +0.70
DiscussionTradeThoughts on holding onto a stock too long
r/investing · Aug 9, 2025
The post expresses regret about holding REGN and its subsequent decline, indicating a negative sentiment.
negative +0.60
DiscussionTradeMeme$REGN - it's like umbrella corporation from Resident Evil and it's on sale
r/wallstreetbets · Jul 22, 2025
The post expresses a bullish view on REGN, highlighting sales, market cap, and potential upside.
positive +0.60
NewsDiscussionMeme$REGN - it's like umbrella corporation from Resident Evil and it's on sale
r/wallstreetbets · Jul 22, 2025
The post frames the stock as 'on sale' and highlights potential upside with the glp1 drug, despite recent failures. Sentiment is bullish.
positive +0.70
Page 1 of 3 (13 total)
AI Analysis
Generated May 27, 2:43 AM
Company Overview

Regeneron Pharmaceuticals, Inc. is a leading biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. Leveraging its proprietary VelociSuite technologies, it maintains a strong competitive position with a robust pipeline and several blockbuster drugs, particularly in ophthalmology and immunology.

Bull Case
  • Robust drug pipeline and proprietary technology platforms (VelociSuite) provide a strong foundation for future growth and innovation.
  • Strong performance of key blockbuster drugs like Eylea and Dupixent, with potential for further label expansion and market penetration.
  • Attractive P/E ratio of 15.5, which may suggest the stock is undervalued relative to its growth prospects and established market position.
  • Significant price decline from its 52-week high (-22.7%) could present a compelling entry point for long-term investors believing in the company's fundamentals.
Bear Case
  • Significant revenue concentration risk with key drugs like Eylea facing increasing competition and biosimilar threats.
  • High R&D costs and inherent risks associated with drug development, including potential pipeline failures or regulatory setbacks.
  • Intense competitive landscape within the pharmaceutical industry, pressuring pricing and market share for existing and pipeline products.
  • Current technical indicators showing strong bearish momentum, with the stock trading well below key moving averages and approaching oversold territory (RSI 31.4).
Recent Performance

REGN has experienced a significant downturn, trading at $634.62, a substantial 22.7% below its 52-week high. The stock is currently in a strong bearish trend, trading well below both its 50-day (-12.4%) and 200-day (-8.1%) moving averages. The RSI-14 of 31.4 indicates persistent selling pressure, nearing oversold conditions, which could imply a potential for stabilization or a short-term rebound if buying interest emerges.

AI-generated analysis is for informational purposes only and does not constitute financial advice.

Not Financial Advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making any investment decisions. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙